Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy

200779 citationsJournal Article

Authors

Helga Kahlert · Chemopharma (Austria)

Roland Suck

Abstract

Due to its reduced IgE reactivity and decreased capacity to activate basophils, but retained T cell reactivity and strong immunogenicity, rBet v 1-FV proved to be a very promising candidate for specific immunotherapy in birch pollen-allergic subjects.

Topics & Keywords

Allergic Rhinitis and Sensitization Food Allergy and Anaphylaxis Research Asthma and respiratory diseases

Publication Details

Published in: International Archives of Allergy and Immunology

Volume 145, Issue 3, pp. 193-206

DOI: 10.1159/000109288

Field-Weighted Citation Impact: 3.11

Command Palette

Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy

Authors

Abstract

Topics & Keywords

Publication Details